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Summary Aromatase is a key enzyme in the conversion of androstenedione and testosterone to oestrone and
oestradiol. Intratumoral aromatase activity is expressed by around 70% of breast carcinomas, but it is not
clear what effect this has on the tumour phenotype. To address this question we expressed human aromatase
in hormone-dependent MCF-7 breast cancer cells. Clone Arom. I expressed aromatase at 1,000 times the
endogenous level in wild-type (WT) cells. Clone Arom. 2 incorporated the expression construct but did not
express aromatase at levels above WT. There was no morphological difference between the two clones and
WT, all three cell lines expressed oestrogen receptor at equivalent levels, and all manifested a mitogenic
response to oestradiol. In steroid-depleted medium Arom. 1 cells showed significant growth enhancement over
WT and Arom. 2, and this growth advantage was increased by exogenous androstenedione or testosterone.
Both the enzyme activity and androgen-stimulated growth of Arom. 1 cells were completely reversible by
aromatase inhibitor CGS 16949A. The Arom. I cell line may contribute to the development of an in vivo
model of intratumoral aromatase, to study the biological significance of this phenomenon.
Oestrogens are important mitogens for human breast cancer
cells in vitro and in vivo, acting directly or by enhancing
secretion of peptide growth factors (Lippman & Dickson,
1990). Oestrogens are synthesised from androgens by an
enzyme complex made up of the cytochrome P450 aromatase
and the flavoprotein NADPH cytochrome P450 reductase
(Lephart & Simpson, 1991). Aromatase activity is expressed
in the endoplasmic reticulum of placenta (Fournet-Dulgerov
et al., 1987) and also in ovarian granulosa cells (McNatty et
al., 1976) and adipose tissue (Simpson et al., 1989), the main
sites of oestrogen synthesis in pre- and post-menopausal
women respectively.
Aromatase activity is detectable in homogenates of
60-70% of primary and metastatic breast cancers. Enzyme
assays reveal activity in the range 5-80 pmol g-' h-', with
0.02-0.9% conversion of androstenedione to oestrone (El) or
testosterone to oestradiol (E2; Varela & Dao, 1978; Miller et
al., 1982, 1990; Bezwoda et al., 1987a; Lipton et al., 1987;
Silva et al., 1989). Opinions vary as to whether this is
sufficient to produce mitogenic concentrations of E2 (Brad-
low, 1982: Miller et al., 1990). Given circulating androgen
levels in the 10-9 M range, it seems likely that the observed
conversion rates for androstenedione and testosterone could
generate El and E2 levels approaching 10-" M, which are
mitogenic to MCF-7 breast cancer cells in vitro (Maclndoe,
1979; Kitiwaki et al., 1992).
Although clinical studies have produced consistent
estimates of the amount of aromatase expressed in breast
cancers, there is little agreement on the biological importance
of intratumoral aromatase. It is not clear whether aromatase
expression correlates with known prognostic indicators such
as tumour size, grade and oestrogen receptor status (Miller et
al., 1982, 1990; Bezwoda et al., 1987a, b; Lipton et al., 1988;
Silva et al., 1989; Bolufer et al., 1992; Esteban et al., 1992).
In order to assess the phenotypic effects of aromatase expres-
sion on breast cancer cells in vitro, we transfected a hormone-
responsive breast cancer cell line with aromatase.
Materials and methods
Aromatase expression plasmid
Human placental poly(A)+ RNA (Cambridge Bioscience,
UK) was reverse transcribed into cDNA with Moloney
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murine leukaemia virus reverse transcriptase (Gibco-BRL)
and oligo dT as previously described (Ashworth, 1993).
Aromatase cDNA was amplified by polymerase chain reac-
tion (PCR) using forward and reverse oligonucleotide
primers CTAAGCTTAAGGAACACAAGATGGTTTTGG
and AAGCGGCCGCTAGTGTTCCAGACACCTGTC, in-
corporating HindIII and NotI restriction sites flanking the
initiation (ATG) and termination (TAG) codons respectively
(Corbin et al., 1988). The 1.5 kb PCR product, correspon-
ding to nucleotides 16-1539 of the published sequence, was
purified by gel electrophoresis (Geneclean; Bio 101, La Jolla,
CA, USA), and digested with HindlII and NotI (Boehringer
Mannheim). This was ligated to HindIII- and NotI-digested
COS cell expression vector pCDM8 (Seed & Aruffo, 1987) to
make construct p3610. DNA sequencing with synthetic
oligonucleotide primers was used to demonstrate the absence
of PCR-induced mutations. The 1.5 kb HindIII-NotI
aromatase insert from p3610 was subcloned into HindIII-
and NotI-digested mammalian expression vector pRc/CMV
(Invitrogen, San Diego, CA, USA) to create plasmid
p3681.
MCF-7 cells
Human MCF-7 breast cancer cells were originally obtained
from the Michigan Cancer Foundation, Detroit, MI, USA.
They were cultured in RPMI-1640 tissue culture medium
containing 10% fetal calf serum (complete medium, CM) at
37C in a humidified atmosphere of 10% carbon dioxide.
Cultures were negative for mycoplasma infection when
stained with Hoechst 33258 (Chen, 1977). MCF-7 cells were
transfected with p3681 by electroporation in HEPES-buffered
saline (20 mM HEPES pH 7.05, 137 mM sodium chloride,
5 mm potassium chloride, 0.7 mM disodium hydrogen phos-
phate, 6 mM dextrose) as described by Chu et al. (1987).
After 48 h 600 yg ml-' G418 (Gibco) was added to the
medium to select for cells carrying the plasmid. After a
further 16 days G418-resistant colonies were picked for indi-
vidual culture, and were maintained in CM with G418 at
600 tLg ml-'
Before experiments in steroid-depleted conditions, MCF-7
cells were cultured for 10 days in phenol red-free RPMI and
5% charcoal-stripped serum (steroid-depleted medium,
SDM), plus 600gg ml-' G418 for resistant clones. For
growth curves, cells were seeded in triplicate at 6 x 104 cells
per well in 1 ml of CM or SDM in the absence or presence of
10-12 to 10-6 M androstenedione or testosterone (Sigma) and
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0-500 nM aromatase inhibitor CGS 16949A (a gift from
Ciba-Geigy Pharmaceuticals). After 1-6 days cells were tryp-
sinised and counted on a Coulter counter. Experiments with
tritiated substrate used [7-3H]testosterone (NEN Dupont,
specific activity 24.6 Ci mmolh ). Cell counts were performed
in triplicate as above, and differences between control and
test means were assessed by analysis ofvariance and Dunnett's
test. Experiments were repeated 2-3 times, and represen-
tative results of individual experiments are shown. Culture
supernatants were snap frozen in liquid nitrogen and stored
at -20°C before product analysis by thin-layer chromato-
graphy (TLC; see below).
Aromatase assay
Aromatase activity was measured in intact cells by tritiated
water release and product isolation assay (Lephart & Simp-
son, 1991). MCF-7 cells were grown to 80% confluence in
25 cm2 culture flasks. After 1 h preincubation in serum-free
RPMI-1640, 10ttl of substrate was added as a solution in
methanol. This was [1p-3H]androstenedione (Amersham) with
unlabelled steroid to obtain the required final concentration.
For kinetic experiments the substrate concentration was
50-500 nM. Aromatase inhibitors were assessed in the
presence of 250 nM [lP-3H]androstenedione. Progesterone
(1 ,M; Sigma) was added to inhibit 5ax-reductase activity
(Zhou et al., 1990). CGS 16949A and 4-hydroxyandro-
stenedione (gifts from Ciba-Geigy Pharmaceuticals) were dis-
solved in methanol and added to the medium to achieve the
correct final concentration. At timed intervals 250 1sl of
supernatant was removed, added to 1.5 ml of ethyl acetate,
shaken and incubated at room temperature for 30 min. The
samples were centrifuged at 1,500g for 15 min. The super-
natant was discarded and 200pl of the aqueous phase was
added to 250 gsl of dextran-coated charcoal (5% charcoal,
0.5% dextran T70) in 0.25% Tween 80. The tubes were
shaken and incubated on ice for 30 min. After centrifugation
(4°C, 3,000 r.p.m., 30 min), 200yl of the supernatant was
counted on a Packard 300C liquid scintillation counter. Cell
monolayers were washed with 50 mm sodium phosphate
buffer pH 7.4, dissolved in 0.5 M sodium hydroxide, and the
protein content was determined by the method of Bradford
(1976). The WT and transfected clones were compared in a
prolonged (24 h) assay which used the method as above, with
16 nM [1p-3H]androstenedione. Tritiated water release that
was inhibited by 500 nM CGS 16949A was considered to
represent specific aromatase activity.
Tissue culture medium was prepared for TLC by extrac-
tion with diethyl ether. The aqueous layer was frozen on dry
ice/acetone permitting separation of the extracted steroids in
ether. The ether was evaporated at 40°C and samples were
reconstituted in dichloromethane (DCM). Standards (tes-
tosterone, androstenedione, El, E2) and triplicate samples
were applied to TLC plates (Merck) and were run for 90 min
in DCM-ethyl acetate-methanol (80:20:1). A Berthold
LB283 TLC linear analyser was used to locate and quantify
radioactive peaks. The products were localised by reference
to the mobility of the standards, rather than by further
chromatography and crystallisation. TLC analysis was per-
formed on triplicate samples from each of two separate
experiments, with very similar results. The results show
values obtained in a single experiment.
Oestrogen receptor assay
Oestrogen receptor (ER) concentrations were measured in
subconfluent cultures growing in CM. Cell homogenates were
prepared using a dismembrator (Braun) and the resultant
powder was suspended in assay buffer. Crude cytosol and
nuclear fractions were prepared by centrifugation (3,000g)
and the cytosols were used for enzyme immunoassay
(Abbott).
Results
Molecular characterisation oftransfected MCF-7 clones
Transient expression of p3610 in COS cells confirmed that
the cDNA encoded active aromatase enzyme (data not
shown). The efficiency of transfection of MCF-7 cells with
p3681 was 1.4%, representing 500 G418-reistant colonies per
pg of DNA. Clones Arom. 1 and Arom. 2 were selected for
further study, and incorporation of p3681 was assessed by
Southern, Northern and Western analysis (Figure 1). The
Southern blot (Figure la) showed bands of 4.8, 5.0, 5.2 and
11 kb, representing the EcoRI-digested endogenous
aromatase gene, in WT, Arom. 1 and Arom. 2 genomic
DNA. An additional 2 kb band representing the transfected
plasmid was detected in Arom. 1 and less intensely in
Arom. 2. In neither case was the intensity similar to that of
the endogenous gene, indicating that the plasmid was present
at lower copy number. Northern analysis revealed a 1.5 kb
aromatase transcript in Arom. 1 cells, and a fainter band of
3.5 kb, probably representing an unspliced nuclear precursor
(Figure lb). Aromatase transcripts were undetectable in WT
and Arom. 2 cells under these conditions. Western blot
analysis (Figure Ic) using polyclonal antibody R-8-2
(Kitiwaki et al., 1989) showed a single band ofapproximately
50 kDa in Arom. 1 but not in Arom. 2 or WT cell lysates.
Thus, aromatase cDNA was incorporated into MCF-7 clones
Arom. 1 and 2, but only Arom. 1 produced significant
aromatase mRNA and protein.
Aromatase activity
Aromatase assay was used to ascertain whether the presence
of aromatase mRNA and protein in MCF-7 cells was leading
to production of functional enzyme. Assays showed
significantly increased aromatase activity in Arom. 1 cells.
Tritiated water release was linear with time up to 2 h. The Km
was 70 nm and the Vm. was 7.1 pmol 3H20 released per mg
of protein per hour, similar to the values of 55.6 nM and
10 pmol mg' h-' reported by Zhou et al. (1990). Stably
expressed aromatase activity was inhibited in Arom. 1 cells
by both CGS 16949A and 4-hydroxyandrostenedione, with
ICm values of 7.4 and 70 nM respectively. At 2 h, WT and
Arom. 2 cells had no detectable aromatase activity. After
24 h incubation, aromatase activity was detected in WT
(12 fmol mg-' protein 24 h-') and Arom. 2 (3 fmolmg'I
24 h-'). This was approximately 1,000 times lower than that
present in Arom. 1 (6120 fmol mg-' 24 h-').
Morphology, ER expression, cell culture
The light microscopic appearances of Arom. 1 and Arom. 2
were not significantly different from WT (not shown). ER
expression was detected in WT, Arom. 1 and Arom. 2 cell
lines at 130 fmol per mg of protein.
When cultured in complete medium (CM) there was no
significant difference in the growth rates of WT, Arom. 1 or
Arom. 2 cells (data not shown). However, a difference in
growth rate was observed in steroid-depleted medium
(SDM): after 6 days the number of Arom. 1 cells was
significantly higher than the number of WT or Arom. 2 cells
(Figure 2). Arom. 1 cells growing in SDM showed further
growth enhancement in the presence of 10-12 to 10-7 M
androstenedione or testosterone, with maximal stimulation
(approximately 130-200% control after 6 days) at 10-11 to
10-`0 M. This response to androgens was not manifest by WT
or Arom. 2 cells. All three cell lines showed a similar
mitogenic response to E2 at 10-12 to 10-7M, with maximal
effects (200-500% control at 6 days) in the presence of
10-11 M E2 (not shown).
In evaluating the growth characteristics of Arom. 1, we
used the Arom. 2 clone as control, since this cell line, like
Arom. 1, had undergone transfection and G418 selection, but
did not express aromatase activity at levels greater than WT.
Figure 3 shows the effect of androstenedione, testosterone orEFFECTS OF AROMATASE OVEREXPRESSION IN MCF-7 CELLS 79
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Figure 1 Southern, Northern and Western analysis of wild-type (WT) MCF-7 cells and G418-resistant clones Arom. 1 and
Arom. 2. a, Approximately 107 cultured cells were used to prepare genomic DNA by salting out (Miller et al., 1988) using the
Stratagene DNA preparation kit according to the manufacturer's instructions. Genomic DNA (10 g) was digested with EcoRI
(Boehringer Mannheim), electrophoresed on a 0.8% agarose gel and transferred to Hybond N+ (Amersham). Bound DNA was
hybridised with a 32P-labelled 2 kb EcoRI fragment of p3681. b, Total RNA was prepared from 107 to 2 x 107 cells by the method
of Chomczynski and Sacchi (1987). RNA (30fg) was electrophoresed on a 1% agarose-formaldehyde gel, transferred to Hybond
N+ and probed with a 32P-labelled 1.5 kb aromatase insert made by digestion of p3681 with HindlII and Notl. c, For Western
analysis, 2-3 x 106 cells were washed with phosphate-buffered saline, pelleted, freeze-thawed and sonicated on maximum power for
15 s. Samples were electrophoresed on a 10% SDS polyacrylamide gel, transferred to nitrocellulose membrane (Schleicher &
Schuell) and probed with polyclonal antibody R-8-2 at 1:1000 dilution (Kitiwaki et al., 1989). The second antibody was an
anti-rabbit HRP conjugate (Promega), and detection was by enhanced chemiluminescence (Kricka, 1990) using ECL reagents
(Amersham) according to the manufacturer's instructions. WT, wild-type MCF-7 cells; Al, Arom. 1 clone; A2 Arom. 2 clone. The
size of molecular weight markers are shown to the left of each blot, in kb for a and b and kDa for c.
E2 10" M on the growth of Arom. 1 and Arom. 2 cells, in
the presence or absence of 500 nM CGS 16949A. In Arom. 1
cells (Figure 3a), CGS 16949A suppressed basal growth
(100 ± 2% to 76 ± 1%, P<0.01) and inhibited the response
to androstenedione (125 ± 1% to 78 ± 1%, P<0.01) and
testosterone (186 ± 4% to 107 ± 1%, P<0.01). Arom. 2 cells
showed a mitogenic response to E2 (160 ± 4%, P<0.01). As
in Arom. 1 cells, this effect was reduced in the presence of
CGS 16949A (142 ± 4%) although it remained significantly
(P<0.01) above control. However Arom. 2 cells showed no
response to androstenedione or testosterone, and CGS
16949A had no inhibitory effect in basal or androgen-
supplemented conditions (Figure 3b).
Culture in SDM with tritiated substrate permitted simul-
taneous assessment of growth and aromatase activity. The
results of culturing Arom. 1 cells with [7-3H]testosterone are
shown in Figure 4. After 24 h culture in medium containing
1.6 nM [7-3H]testosterone, product isolation analysis revealed
that 46% of the substrate had been converted to E2. Dihyd-
rotestosterone, the product of 5a-reductase activity, has very
similar mobility to E2 on TLC, and in theory could con-
taminate the 'E2' peaks generated by Arom. 1. However,
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significant contamination is thought to be unlikely because
little or no 'E,' was generated by Arom. 2 cells, which should
have similar 5o-reductase activity (see below, Figure 4c). By
day 6 Arom. 1 cells had converted 100% of the substrate to
oestrogen (16% E,, 84% E,; Figure 4a). This was associated
with significant enhancement of cell growth on day 6
(4.6 ± 0.2 x lO5 cells per well compared with 1.6 ± 0.1 x l05
in control cultures, P<0.01, Figure 4c). In both day 1 and
day 6 samples, aromatisation of 1.6 nM [7-3H]testosterone
was completely inhibited by 500 nM CGS 16949A. Cell
numbers were significantly lower than in the absence of CGS
16949A (2.6 ± 0.7 v.s 4.6 ± 0.2 x 105, P<0.01), and not
significantly different from the cell number in control cul-
tures. The higher [7-'H]testosterone concentration of 16 nM
was almost completely converted to E2 (82%) by day 1. On
day 6, 63.5% of tritiated product was identified as E2, and
22.5% was an unidentified peak. There was significant
growth enhancement (2.6 ± 0.4 x 105 cells per well, P<0.05),
although the effect here was less than in cultures supp-
lemented with 1.6 nM [7-3H]testosterone, suggesting produc-
tion of a higher concentration of E, than the 10 to 10 9 M
range previously found to be optimal. As at the lower sub-
strate concentration, CGS 16949A completely suppressed
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Figure 2 Growth in steroid-depleted medium. WT, Arom. I or
Arom. 2 cells were seeded in triplicate at 6 x 104 cells per well in
SDM. After 6 days the cells were trypsinised and counted on a
Coulter counter. Bars represent the mean + s.e.m. of triplicate
cell counts. *The number of Arom. I cells was significantly
greater (P<0.01 by Dunnett's test) than WT or Arom. 2.
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conversion of testosterone to E, during the first 24 h. By day
6 there had been negligible conversion to E, (8%), 62.5%
steroid remained as testosterone and 21.50% was in an
unidentified peak. This suppression of aromatase activity was
associated with growth delay (1.1 ± 0.20 x 10t vs
2.6 ± 0.4 x 105 in the absence of CGS 16949A, P<0.01),
with cell nurhbers falling to the level observed in control
cultures.
Results of the parallel experiment on Arom. 2 are shown in
Figure 4b and d. No significant aromatase activity was
detected in these cells on day 1, or on day 6 at the lower
[7-3H]testosterone concentration, 1.6 nM. After 6 days in the
presence of 16 nM substrate, there was 13% conversion to E,.
This was not suppressed by CGS 16949A. Arom. 2 cell
numbers showed no significant differences from control in the
presence or absence of [7-3H]testosterone or aromatase
inhibitor.
Discussion
The aim of this study was to assess the biological significance
of intratumoral aromatase expression, particularly in areas in
which studies of clinical material have yielded conflicting
data. To this end we first sought to confirm that transfected
MCF-7 cells expressed aromatase, comparing the level of
enzyme activity with that detectable in clinical samples of
breast cancer.
Molecular analysis confirmed incorporation of aromatase
cDNA into MCF-7 clones Arom. 1 and Arom. 2. In both
clones the transfected plasmid was present at lower copy
number than the endogenous aromatase gene. A similar
finding, compatible with amplification of the endogenous
gene, was made by Zhou et al. (1990) when expressing
aromatase in mammalian cells for screening of new
inhibitors. We detected high levels of expressed aromatase by
Northern and Western analysis in clone Arom. 1 but not WT
or Arom. 2. As we have previously reported (Ryde et a!.,
1992), WT cells have detectable aromatase activity, which we
and others (Zhou ct al., 1990; Pizzini et al., 1992) found too
low for full kinetic analysis. Despite incorporation of the
expression construct, Arom. 2 cells did not have aromatase
activity above WT levels. The reason for this is unclear.
Enzyme assay of Arom. 1 revealed a Km of 7.1 pmol
mg-' h-'. The results of 24 h assay showed these cells to
express approximately 1,000 times more aromatase activity
than WT or Arom. 2 cells. We observed 100% conversion of
physiological levels of testosterone (10-9 to 10-8 M) to oest-
rogens in Arom. 1 cells (Figure 4). This represents 100- 1,000
times the level of aromatase activity in clinical tumour speci-
mens (Varela & Dao. 1978: Miller et al., 1982, 1990; Lipton
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Figure 3 Response of Arom. 1 or Arom. 2 cells to androgens, E, and CGS 16949A. Cells were grown for 6 days in SDM with no
additives (control) or 1)- M androstenedione, testosterone or E, in the absence or presence of 500 nm CGS 16949A. Bars
represent the mean + s.e.m. of triplicate counts. a, Arom. 1; b. Arom. 2.EFFECTS OF AROMATASE OVEREXPRESSION IN MCF-7 CELLS 81
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Figure 4 Aromatase activity and growth in the presence of [7-3H]testosterone. a and b show product isolation analysis of culture
supernatants from a, Arom. 1 and b, Arom. 2 after 1 and 6 days culture in SDM with 1.6 or 16 nM [7-3H]testosterone in the
absence or presence of 500 nm CGS 16949A. The bars represent the means of triplicate analyses; all s.e.m.s were <10% means. c
and d show growth curves (mean ± s.e.m. of triplicate counts) for c, Arom. 1 and d, Arom. 2 in SDM with no additives (control) or
1.6 or 16 nM [7-3H]testosterone alone or with 500 nm CGS 16949A. l, control (no testosterone); *, control + CGS; 0, 1.6 nM
testosterone; 0, 1.6 nm testosterone + CGS; A, 16 nm testosterone; A, 16 nm testosterone + CGS.
et al., 1987; Silva et al., 1989). Enzyme activity in clinical
tumour homogenates reflects aromatase expressed by the
tumour cells, and at lower levels, by breast adipose cells
(Perel et al., 1982). Extracellular matrix makes no contribu-
tion; indeed aromatase activity is higher in highly cellular
tumours than in those of moderate/low cellularity (Miller et
al., 1990). This hetergeneous expression pattern could be
modelled in vitro or in vivo by mixing Arom. 1 with a 100- to
1,000-fold excess of WT or Arom. 2 cells.
Having characterised the aromatase activity of WT MCF-7
cells and the two transfected clones, we compared cells with
high and low aromatase activity with regard to morphology,
ER status, growth pattern and response to aromatase
inhibitors. Although an excess of aromatase-positive tumours
have been reported to be high grade (Silva et al., 1989),
Lipton et al. (1988) found no correlation between intra-
tumoral aromatase expression and degree of differentiation.
In support of this conclusion we found that overexpression
of aromatase had no effect on the morphology of cultured
cells. Similarly we found no difference in levels of ER expres-
sion between Arom. 1 and WT cells. Some clinical studies
have found a positive correlation between intratumoral
aromatase expression and ER positivity (Miller et al., 1982,
1990; Bolufer et al., 1992). Others suggest that aromatase-
positive tumours are more often ER negative (Abul-Haji et
al., 1979; Esteban et al., 1992), and some have found no
correlation (Varela & Dao, 1978; Lipton et al., 1987; Bez-
woda et al., 1987a; Silva et al., 1989).
Most breast cancers are thought to be hormone dependent
early in their natural history (Lippman & Dickson, 1990),
and so aromatase activity may affect the growth of the
tumour. Local oestrogen production may enhance growth of
the aromatase-positive cells and, in a paracrine fashion, adja-
cent aromatase-negative cells. Several studies have attempted
to correlate aromatase activity with clinical prognostic fac-
tors and response to treatment (Bezwoda et al., 1987a,b;
Silva et al., 1989; Miller et al., 1990; Bolufer et al., 1992). In
our in vitro model we found no growth difference in complete
medium, as serum provides sufficient oestrogen for optimal
growth. However in SDM Arom. 1 cells grew faster than WT
or Arom. 2 (Figure 2). We have no definite explanation for
this observation, but it is consistent with a response to
residual androgen remaining in SDM after charcoal stripping
of serum. There was more marked growth enhancement on
addition of androstenedione or testosterone. We did not
observe a response to androgens in Arom. 2 or WT cells;
neither cell line grew in the absence of exogenous oestrogen.
However, there is evidence for heterogeneity of aromatase
expression in WT MCF-7 cells, sufficient to permit some
sublines to grow in androgen-supplemented SDM (Darbre &
Daly, 1989; Kitiwaki et al., 1992).
Finally we assessed the effect of aromatase inhibitors on
WT, Arom. 1 and Arom. 2 cells. Both CGS 16949A and
4-hydroxyandrostenedione inhibited the aromatase activity of
Arom. 1 cells, with IC50 values (7.4 and 70 nM respectively)
similar to results reported for human placental microsomes (5
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and 62 nM; Bhatnagar et al., 1989). This suggests that the
Arom. 1 cells may be suitable for use in the screening of new
inhibitors. CGS 16949A suppressed basal growth of Arom. 1
cells to approximately 75% of control. This could have been
due to direct toxicity, although there was no growth inhibi-
tion in Arom. 2 cells cultured under basal or androgen-
supplemented conditions (Figure 3). Alternatively, it could be
due to suppression of the mitogenic response to any residual
androgen remaining in SDM, but we have no direct evidence
for this. CGS 16949A also caused complete suppression of
the mitogenic effect of 10-11 M androstenedione or tes-
tosterone. Experiments with tritiated substrates enable us to
correlate directly aromatase activity and growth enhance-
ment, and to assess the inhibition of enzyme activity and
growth by CGS 16949A. Here we used androgen concentra-
tions of 1.6-16 nM, equivalent to circulating levels in post-
menopausal women (Judd et al., 1974). We did not purify
'oestrogens' separated by TLC, but significant contamination
of these peaks with other products seemed unlikely for
several reasons. The negligible loss of testosterone to other
peaks (in particular those associated with El or E2) in
Arom. 2 cells indicates little underlying metabolism of this
precursor to oestrogens or other products coincident on
TLC. In Arom. 1 cells there was good correlation between
conversion of testosterone to E2, which was generally com-
plete after 24 h, and growth enhancement observed on day 6.
CGS 16949A, a highly selective aromatase inhibitor, caused
virtual obliteration of 'oestrogen' peaks generated by
Arom. 1 cells. This was accompanied by complete suppres-
sion of androgen-stimulated growth, again supporting the
view that oestrogens were the main products of testosterone
metabolism by the Arom. 1 clone.
In summary.we have developed a clone of MCF-7 cells
which stably overexpresses aromatase at 1,000 times the level
in WT cells. This had no detectable effect on morphology,
ER expression or response to E2. However, there was signifi-
cant growth enhancement in steroid-depleted conditions, and
this growth advantage over WT cells was further enhanced
by exogenous androgens. These changes were fully reversible
by aromatase inhibitors. We plan to evaluate the growth
characteristics of Arom. 1 cells in vivo. The ability to
manipulate aromatase expression by breast cancer xenografts
should help to clarify the significance of intratumoral
aromatase detectable in clinical breast tumours.
This work was supported by the Cancer Research Campaign and the
Medical Research Council.
Abbreviations: El, oestrone; E2, oestradiol; ER, oestrogen receptor;
PCR, polymerase chain reaction; K,,,, substrate concentration pro-
ducing half-maximal velocity; Vmax, maximal velocity; IC50, drug
concentration causing 50% inhibition of enzyme activity.
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